icon_star paper   Hepatitis C Articles (HCV)  
Back grey arrow rt.gif
 
 
Schering Plough Ends Celgosivir Deal
 
 
  Update on Migenix Agreement with Schering-Plough for Hepatitis C Virus Treatment
 
VANCOUVER and SAN DIEGO, June 27, 2007 /PRNewswire-FirstCall/ - MIGENIX Inc. , a clinical-stage developer of drugs for infectious diseases, has received notice that Schering-Plough Corporation ("Schering") will not enter into a second period of exclusivity to negotiate terms of a license agreement for MIGENIX's Hepatitis C Virus ("HCV") product, celgosivir. MIGENIX is, therefore now free to advance discussions with other interested parties. Schering has expressed a willingness to consider providing MIGENIX with guidance on study design and drug supplies in support of celgosivir's further clinical development. The exclusivity with Schering arose in connection with the terms of a Material Transfer and License Option Agreement between MIGENIX and Schering related to a recently completed Phase II non-responder study of celgosivir.
 
Jim DeMesa, M.D., President and CEO of MIGENIX stated, "The results from the recent non-responder study demonstrated clinically significant benefits when celgosivir was added to the standard of care (pegylated interferon plus ribavirin). Those results have increased the interest of both the clinical community and of several pharma and biotech companies active in HCV product development. Because celgosivir offers a unique mechanism of action, once-daily oral dosing, a good safety profile, and has demonstrated synergy with other HCV treatments, we are optimistic about the potential of celgosivir to contribute to the treatment of HCV patients."
 
About Celgosivir (MX-3253)
 
Celgosivir, an oral inhibitor of alpha-glucosidase I, is currently the only anti-HCV drug in clinical development that acts on host-directed glycosylation. In preclinical studies, celgosivir has shown excellent in vitro synergy with various interferons in the clinic or in development including Pegasys, PEG-Intron, Infergen, Alferon and IFN-omega (with or without ribavirin) and other drugs in development for the treatment of HCV (e.g. polymerase inhibitors) and therefore has the potential to be included in many combination therapy approaches to improve efficacy in anti-HCV treatment.
 
The Phase II non-responder combination study reported April 11, 2007 was designed to determine, over 12 weeks of treatment, the efficacy, safety, and tolerability of celgosivir in combination with peginterferon alfa-2b, with or without ribavirin, in HCV-positive (genotype 1) patients who were non-responders or partial responders to prior therapy with optimized pegylated interferon and ribavirin. The following is a summary of the non-responder data:
 
- a 42% Early Virologic Response ("EVR") with the triple combination
compared to a 10% EVR in the control treatment arm.
(x) EVR = 2 log10 or greater HCV viral load reduction at
12 weeks.
 
- a mean HCV viral load reduction ("VLR") of 1.63 log10 (triple
combination) compared to a 0.92 log10 reduction (control).
 
- 90% viral load reduction (1 log10) reduction, or greater, at 12 weeks
in 66% (8/12) of the triple combination patients, compared to only
40% (4/10) in patients in the control treatment.
 
- EVR in 57% of null responders (4/7) in the triple therapy arm (null
responders = patients who have not achieved greater than a
0.4 log10 viral load reduction on prior treatment with optimized
peg-interferon plus ribavirin).
 
Celgosivir combination therapy was well tolerated and resulted in no significant adverse events. As expected from previous experience, the most frequent side effects related to celgosivir were gastrointestinal in nature and were generally mild. Other frequently observed side effects were fatigue and flu-like symptoms - which are side effects usually associated with pegylated interferon and ribavirin. Fifty of 57 patients entering the study completed all 12 weeks of treatment.
 
Material Transfer and License Option Agreement with Schering-Plough
 
Under the terms of the Agreement, Schering supplied PEGETRON(TM) (peginterferon alfa-2b powder for solution plus ribavirin 200 mg capsules) as well as certain technical and laboratory support and other services for MIGENIX's celgosivir Phase II combination study in chronic HCV patients and a related extension protocol. In addition, the Agreement granted Schering limited periods of exclusivity for data review of clinical trial results and for the negotiation of a license agreement.
 
About HCV
 
HCV, the most common chronic blood-borne infection in the United States, causes inflammation of the liver and may progress to more serious complications such as cirrhosis of the liver, liver cancer and death. Approximately 2.7 million people in the United States are chronically infected with HCV, and the Centers for Disease Control and Prevention (CDC) estimates that by the year 2010, the number of deaths attributed annually to HCV could surpass that due to HIV/AIDS in the US. Worldwide, the World Health Organization estimates that 170 million individuals have chronic HCV infection, with 3 to 4 million new infections each year.
 
Therapy for HCV currently employs a drug combination approach, which is anticipated to continue in the future. The current standard of care for treatment-naive chronic hepatitis C is pegylated interferon combined with ribavirin, which fails to provide a satisfactory outcome for approximately 50% of patients infected with HCV genotype 1 (the most prevalent genotype in North America). In addition, these drugs can cause significant side effects that limit tolerance to therapy, or a frequent lack of sustained treatment response.
 
About MIGENIX
 
MIGENIX is committed to advancing therapy, improving health, and enriching life by developing and commercializing drugs primarily in the area of infectious diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C infections (Phase II and preclinical), the prevention of catheter-related infections (Phase III) and the treatment of dermatological diseases (Phase II). MIGENIX is headquartered in Vancouver, British Columbia, Canada with US operations in San Diego, California. Additional information can be found at www.migenix.com.
 
"Jim DeMesa"
James M. DeMesa, M.D.
President & CEO
 
 
 
 
  icon_paper_stack View Older Articles   Back to Top   www.natap.org